Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy

利用整合素信号传导克服免疫治疗耐药性

基本信息

  • 批准号:
    10533342
  • 负责人:
  • 金额:
    $ 43.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-12-01 至 2024-11-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The potential of checkpoint immunotherapy to combat cancer has been established in several cancer types. However, in pancreatic ductal adenocarcinoma (PDAC), checkpoint immunotherapy has not led to clinical benefit. Although multiple factors likely contribute, one significant factor is the extensive infiltration of PDAC by multiple lineages of immunosuppressive myeloid cells. Therefore, one promising therapeutic strategy is the targeting these myeloid cells to improve T cell-mediated immunity. These realizations have led to a significant number of clinical trials combining myeloid targeted agent with checkpoint immunotherapy. However, all current therapeutic strategies are subject to compensatory actions by untargeted subsets of monocytes, granulocytes, and/or tissue resident macrophages, which may ultimately limit therapeutic efficacy. To overcome this limitation, our team has developed a small molecule allosteric agonist of CD11b, ADH-503. Our data will clearly demonstrate: 1) CD11b-agonism both rapidly repolarizes TAMs to support anti-tumor immunity while simultaneously blunting the recruitment of multiple lineages of suppressive myeloid cells without the compensatory mechanisms seen with other myeloid-targeting agents. 2) CD11b-agonist-induce myeloid reprograming reawakens T cell immunity that in-turn significantly limit disease progression. 3) The combination of CD11b-agonist with checkpoint immunotherapy leads to dramatic tumor regression and long- term survival in PDAC models that are otherwise completely resistant to PD-1 therapy. These stunning data drive our hypothesis that CD11b agonism reprograms the TME to overcome resistance to checkpoint immunotherapy. To test this, we will: Aim 1: Determine the molecular mechanisms by which CD11b-agonism directly impacts myeloid cells. Aim 2: Determine the cellular mechanism(s) by which CD11b-agonism enhances T cell immunity. Aim 3: Determine if chemotherapy or radiation therapy better maximize the anti-tumor immunity and the efficacy generated by ADH-503 plus checkpoint immunotherapy. Impact: These studies investigate a new approach in current clinical development that can render PDACs responsive to immunotherapy.
项目概要 检查点免疫疗法对抗癌症的潜力已在多种癌症中得到证实 类型。然而,在胰腺导管腺癌(PDAC)中,检查点免疫疗法并未导致 临床获益。虽然可能有多种因素造成,但一个重要因素是广泛渗透 PDAC 由多个谱系的免疫抑制性骨髓细胞组成。因此,一种有前景的治疗策略 是针对这些骨髓细胞来改善 T 细胞介导的免疫力。这些认识导致了 大量临床试验将骨髓靶向药物与检查点免疫疗法相结合。 然而,目前所有的治疗策略都受到非靶向子集的补偿作用的影响。 单核细胞、粒细胞和/或组织驻留巨噬细胞,这可能最终限制治疗效果。 为了克服这一限制,我们的团队开发了一种CD11b的小分子变构激动剂ADH-503。 我们的数据将清楚地证明:1) CD11b 激动作用均可快速使 TAM 重新极化以支持抗肿瘤 免疫,同时削弱抑制性骨髓细胞的多个谱系的募集 没有其他骨髓靶向药物所见的补偿机制。 2) CD11b-激动剂-诱导 骨髓重编程重新唤醒 T 细胞免疫,从而显着限制疾病进展。 3) 的 CD11b 激动剂与检查点免疫疗法的结合可导致肿瘤显着消退并长期有效 对 PD-1 治疗完全耐药的 PDAC 模型的长期生存。这些惊人的数据 推动我们的假设,即 CD11b 激动剂会重新编程 TME 以克服对检查点的抵抗 免疫疗法。为了测试这一点,我们将: 目标 1:确定 CD11b 激动直接影响骨髓细胞的分子机制。 目标 2:确定 CD11b 激动增强 T 细胞免疫的细胞机制。 目标 3:确定化疗或放疗是否能更好地最大限度地提高抗肿瘤免疫力和 ADH-503 联合检查点免疫疗法产生的疗效。 影响:这些研究调查了当前临床开发中的一种新方法,可以使 PDAC 对免疫治疗有反应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David G DeNardo其他文献

Targeting focal adhesion kinase reprograms the pancreatic tumor microenvironment and renders pancreas cancer responsive to checkpoint immunotherapy
  • DOI:
    10.1186/2051-1426-3-s2-p400
  • 发表时间:
    2015-01-01
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Hong Jiang;Brett Knolhoff;Yu Zhu;John Herndon;Irina Shapiro;David Weaver;Jonathan Pachter;Andrea Wang-Gillam;David G DeNardo
  • 通讯作者:
    David G DeNardo
cmFPA008, an anti-mouse CSF-1R antibody, combines with multiple immunotherapies to reduce tumor growth in nonclinical models
  • DOI:
    10.1186/2051-1426-3-s2-p351
  • 发表时间:
    2015-11-04
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    David Bellovin;Nebiyu Wondyfraw;Anita Levin;David G DeNardo;Emma Masteller;Thomas Brennan
  • 通讯作者:
    Thomas Brennan

David G DeNardo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David G DeNardo', 18)}}的其他基金

Research Project Pancreatic Cancer
胰腺癌研究项目
  • 批准号:
    10715023
  • 财政年份:
    2023
  • 资助金额:
    $ 43.58万
  • 项目类别:
Project 1: Employing CD11b-Agonists to Render PDAC Responsive to Immunotherapy
项目 1:利用 CD11b 激动剂使 PDAC 对免疫疗法产生反应
  • 批准号:
    10708574
  • 财政年份:
    2023
  • 资助金额:
    $ 43.58万
  • 项目类别:
The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity
转移部位对树突状细胞驱动的肿瘤免疫的影响
  • 批准号:
    10738428
  • 财政年份:
    2023
  • 资助金额:
    $ 43.58万
  • 项目类别:
Washington University SPORE in Pancreatic Cancer
华盛顿大学 SPORE 在胰腺癌中的应用
  • 批准号:
    10708572
  • 财政年份:
    2023
  • 资助金额:
    $ 43.58万
  • 项目类别:
Re-wiring PDAC Tumor Immunity Through Dendritic Cells
通过树突状细胞重新连接 PDAC 肿瘤免疫
  • 批准号:
    10280010
  • 财政年份:
    2021
  • 资助金额:
    $ 43.58万
  • 项目类别:
Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity
靶向粘着斑激酶以改善 RT 诱导的肿瘤免疫
  • 批准号:
    10616539
  • 财政年份:
    2020
  • 资助金额:
    $ 43.58万
  • 项目类别:
Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity
靶向粘着斑激酶以改善 RT 诱导的肿瘤免疫
  • 批准号:
    10428469
  • 财政年份:
    2020
  • 资助金额:
    $ 43.58万
  • 项目类别:
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy
利用整合素信号传导克服免疫治疗耐药性
  • 批准号:
    10057373
  • 财政年份:
    2019
  • 资助金额:
    $ 43.58万
  • 项目类别:
Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy
利用整合素信号传导克服免疫治疗耐药性
  • 批准号:
    10307534
  • 财政年份:
    2019
  • 资助金额:
    $ 43.58万
  • 项目类别:
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
肿瘤和间质联合靶向改善胰腺癌对免疫治疗的反应
  • 批准号:
    9077612
  • 财政年份:
    2016
  • 资助金额:
    $ 43.58万
  • 项目类别:

相似海外基金

Treatment research by the suppression of secretory phenomenon associated with cellular senescence in mouse prostate cancer model
通过抑制小鼠前列腺癌模型中与细胞衰老相关的分泌现象进行治疗研究
  • 批准号:
    21K09409
  • 财政年份:
    2021
  • 资助金额:
    $ 43.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Pancreatic cancer biomarker research by the exosome proteome analysis of the HGD rat pancreatic cancer model
HGD大鼠胰腺癌模型的外泌体蛋白质组分析研究胰腺癌生物标志物
  • 批准号:
    21K07910
  • 财政年份:
    2021
  • 资助金额:
    $ 43.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identifying and manipulating molecular mechanisms controlling cancer stem cell metastatic potential in a human oral cancer model.
识别和操纵控制人类口腔癌模型中癌症干细胞转移潜力的分子机制。
  • 批准号:
    MR/V009494/1
  • 财政年份:
    2021
  • 资助金额:
    $ 43.58万
  • 项目类别:
    Research Grant
Establishment of near-infrared photoimmunotherapy targeting CD73 using mouse lung cancer model
小鼠肺癌模型建立靶向CD73的近红外光免疫疗法
  • 批准号:
    21K07189
  • 财政年份:
    2021
  • 资助金额:
    $ 43.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Synthetic Lethality Related to Over-Expression of Telomerase Reverse Transcriptase in a Prostate Cancer Model
前列腺癌模型中与端粒酶逆转录酶过度表达相关的合成致死率
  • 批准号:
    467101
  • 财政年份:
    2021
  • 资助金额:
    $ 43.58万
  • 项目类别:
    Studentship Programs
Development of a Vascularized Brain Cancer Model with Built-in Immunity and Lymphatic System for Immune Cell/Drug Delivery and Clearance
开发具有内置免疫和淋巴系统的血管化脑癌模型,用于免疫细胞/药物输送和清除
  • 批准号:
    565148-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 43.58万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Characterizing the Behaviour of Myeloid-Derived Suppressor Cells in a 3D In Vitro cancer Model
表征 3D 体外癌症模型中骨髓源性抑制细胞的行为
  • 批准号:
    551138-2020
  • 财政年份:
    2020
  • 资助金额:
    $ 43.58万
  • 项目类别:
    University Undergraduate Student Research Awards
Patient Derived Cancer Model (PDCM) Finder
患者衍生癌症模型 (PDCM) 查找器
  • 批准号:
    10260591
  • 财政年份:
    2020
  • 资助金额:
    $ 43.58万
  • 项目类别:
Establishment of visualizing oral cancer model and development of clinical ultrasonographic examination which detects initial cervical metastatic lymph node by oral cancer
可视化口腔癌模型的建立及口腔癌早期颈部转移淋巴结临床超声检查的进展
  • 批准号:
    20K10140
  • 财政年份:
    2020
  • 资助金额:
    $ 43.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Advancing precision medicine through development of the canine comparative cancer model
通过开发犬类比较癌症模型推进精准医疗
  • 批准号:
    9910776
  • 财政年份:
    2020
  • 资助金额:
    $ 43.58万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了